Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$659.22 USD

659.22
4,697,720

+19.79 (3.10%)

Updated Aug 13, 2025 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 245)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

by Zacks Equity Research

J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.

Zacks Equity Research

Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

by Zacks Equity Research

Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.

Zacks Equity Research

Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Allergan's Depression Candidate Fails in Studies, Stock Down

by Zacks Equity Research

Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%

Zacks Equity Research

Lilly's Emgality Gets FDA Priority Review for Cluster Headache

by Zacks Equity Research

Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.

Zacks Equity Research

J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression

by Zacks Equity Research

J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression

Zacks Equity Research

Lilly to Bring Half-Priced Version of Popular Humalog Insulin

by Zacks Equity Research

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

Zacks Equity Research

Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales

by Zacks Equity Research

Radius Health (RDUS) posts narrower-than-expected Q4 loss as Tymlos sales gain traction and capture additional market share.

Zacks Equity Research

Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.

Zacks Equity Research

United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.

Zacks Equity Research

Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft

Zacks Equity Research

Merck to Buy Immunotherapy Developer Immune Design for $300M

by Zacks Equity Research

Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.

Zacks Equity Research

Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

by Zacks Equity Research

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

Swarup Gupta headshot

Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review

by Swarup Gupta

The index endured a holiday-shortened but volatile week.

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Sweta Killa

Sector ETF report for PPH

Zacks Equity Research

Allergan Responds to Investor's Call for CEO/Chair Role Split

by Zacks Equity Research

Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.

Zacks Equity Research

Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study

by Zacks Equity Research

Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.

Zacks Equity Research

Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

by Zacks Equity Research

Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

Zacks Equity Research

Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

by Zacks Equity Research

Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.

Zacks Equity Research

Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.

Zacks Equity Research

Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Zacks Equity Research

Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.

Zacks Equity Research

5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

by Zacks Equity Research

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

Zacks Equity Research

Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down

by Zacks Equity Research

Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.